Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of our study is to evaluate the effect of use of prophylactic vaginal progesterone on the incidence of severe preterm delivery, defined as delivery before 33+6 weeks in women with a short cervical length of 15mm.
| Condition | Intervention | Phase |
|---|---|---|
|
Preterm Birth Pregnancy Trimester, Second |
Drug: Micronised progesterone (Utrogestan) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Double-Blind Primary Purpose: Prevention |
| Official Title: | Randomised Study to Examine the Effectiveness of Progesterone in Preventing Severe Preterm Delivery |
- Spontaneous delivery before 34 completed weeks (238 days) of gestation.
- Birth weight, fetal or neonatal death, major adverse outcome before discharge from hospital and need for neonatal special care (admission to special care baby unit, phototherapy, treatment of proven or suspected sepsis, or blood transfusion).
| Estimated Enrollment: | 250 |
| Study Start Date: | September 2003 |
| Estimated Study Completion Date: | November 2006 |
BACKGROUND The results of randomized studies have shown that the prophylactic use of progesterone in women who previously delivered prematurely reduces the risk of recurrence. Asymptomatic women found to have a short cervix (< 15 mm) at mid-gestation are at greatly increased risk for spontaneous early preterm delivery and it is uncertain whether in such women the risk is reduced by progesterone.
METHODS Cervical length was measured by transvaginal sonography at 22 (range 20-25) weeks in 24,620 pregnant women attending for routine antenatal care. The cervix was 15 mm or less in 413 (1.7%), and 250 (60.5%) of these women participated in a randomized study of vaginal progesterone (200 mg per night) vs identical-looking placebo, between 24 and 34 weeks. Primary outcome was the frequency of spontaneous delivery before 34 weeks (238 days) of pregnancy. Analysis was performed according to the intention-to-treat principle.
Eligibility| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- All women with singleton or twin pregnancies attending for routine ultrasound examination at 20-25 weeks of gestation with a short cervical length (<15 mm).
Exclusion Criteria:
- Women with major fetal abnormalities,
- Painful regular uterine contractions, or history of ruptured membranes or cervical cerclage in-situ were excluded from screening.
Contacts and Locations| Brazil | |
| Hospital do Servidor Publico Estadual-FMO | |
| Sao Paulo, Brazil | |
| Chile | |
| Hospital Clinico Universidad de Chile | |
| Santiago, Chile | |
| Greece | |
| University Hospital | |
| Larissa, Greece | |
| United Kingdom | |
| Darent Valley Hospital | |
| Kent, United Kingdom | |
| King's College Hospital NHS Foumdation Trust | |
| London, United Kingdom, SE5 9RS | |
| Queen Elizabeth Hospital, NHS Trust Woolwich | |
| London, United Kingdom, SE18 4QH | |
| University Hospital of Lewisham | |
| London, United Kingdom, SE13 6LH | |
| Southend University Hospital, Essex | |
| London, United Kingdom, SS0 0RY | |
| Principal Investigator: | Kypros H Nicolaides, MD, PhD | King's College London |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00422526 History of Changes |
| Other Study ID Numbers: | 03WH13 |
| Study First Received: | January 15, 2007 |
| Last Updated: | January 16, 2007 |
| Health Authority: | United Kingdom: Department of Health United Kingdom: Medicines and Healthcare Products Regulatory Agency United Kingdom: National Health Service United Kingdom: Research Ethics Committee |
Keywords provided by King's College Hospital NHS Trust:
|
Preterm delivery, short cervix, progesterone |
Additional relevant MeSH terms:
|
Premature Birth Obstetric Labor, Premature Obstetric Labor Complications Pregnancy Complications Progesterone |
Progestins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 17, 2013